Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
  • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• This invention relates to processes and intermediates for the its preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one is useful in the treatment of psychotic disorders.
• the present invention provides a process for preparing the compound of the formula ##STR3## which comprises treating a compound of the formula ##STR4## wherein R 2 is hydrogen, CN or CO 2 R 1 and R 1 is hydrogen or (C 1 -C 6 )alkyl with a reducing agent with the proviso that when R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl the product of the reduction is heated with an acid.
• the invention also provides a process for preparing a compound of the formula II
• R 2 and R 1 are both hydrogen by heating the compound of the formula II wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 in the presence of an aqueous acid:
• R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 by treating the compound of the formula ##STR7## with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 2 is CN or CO 2 R 1 , respectively, and R 1 is (C 1 -C 6 )alkyl in the presence of a base.
• the invention provides a process for preparing the compound of the formula III by treating the compound of the formula ##STR8## with a reducing agent.
• a process for preparing the compound of formula IV which comprises treating the compound of the formula ##STR9## with the compound of the formula ##STR10## in the presence of a (C 1 -C 6 ) alkanoic acid.
• Another aspect of the invention provides a process for preparing the compound of the formula V which comprises treating a compound of the formula ##STR11## with an enamine forming compound selected from the group consisting of t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals in an inert solvent.
• Yet another aspect of the invention provides a process for preparing a compound of the formula VII by treating a compound of the formula ##STR12## wherein R 2 is CO 2 R 1 or CN and R 1 is (C 1 -C 6 )alkyl with an acid at an elevated temperature.
• a process for preparing a compound of the formula VIII which comprises treating the compound of the formula ##STR13## with a compound of the formula R 2 --CH 2 --CO 2 R 1 wherein R 2 is CO 2 R 1 or CN and R 1 is (C 1 -C 6 )alkyl in the presence of a base.
• Another aspect of the invention provides a process for preparing the compound of the formula IX which comprises treating the compound of the formula ##STR14## with the compound of the formula ##STR15## in the presence of (CH 3 CO 2 ) 3 NaBH and acetic acid.
• Another aspect of the invention provides a process for preparing the compound of the formula ##STR16## which comprises the steps of
• step 4) treating the product of step 3) with an acid at an elevated temperature to form a the compound of formula II wherein R 2 and R 1 are both hydrogen;
• step 5 treating the product of step 4 with a (C 1 -C 6 )alkanol in the presence of an acidic esterification catalyst to form the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl; or
• a compound of the formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl is treated with a reducing agent and the resulting product is heated with an acid to prepare compound of formula I.
• a reaction inert solvent Suitable reducing agents are sodium hydrosulfite, hydrogen in the presence of a hydrogenation catalyst, iron in acetic acid, zinc and CaCl 2 in acetic acid and NaH 2 PO 2 in the presence of Pd/C.
• a preferred reducing agent is sodium hydrosulfite.
• the temperature of the reduction stage is from about 10° to about 100° C.
• reaction temperature is preferably from about 65° to about 80° C.
• the temperature at the acid treatment stage is from about 50° to about 110° C.
• Acids which are useful in this stage are strong mineral acids such as concentrated hydrochloric and 6N sulfuric acids.
• Suitable solvents are water and water miscible solvents such as (C 1 -C 6 )alkanols, tetrahydrofuran (THF) and dioxane and mixtures thereof.
• a compound of formula II wherein R 2 is hydrogen and R 1 is hydrogen or (C 1 -C 6 )alkyl is converted to the compound of formula I by treatment with a reducing agent. Suitable conditions for the reduction are indicated above.
• the compounds of formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl are prepared by reacting the compound of formula III with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 , respectively, in the presence of a base.
• the reaction is, generally, effected in an aprotic polar solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO) or N-methylpyrrolidone at a temperature from about 25° to about 100° C.
• Suitable bases include alkali metal hydroxides and hydrides and hindered (C 1 -C 6 )alkoxides such as KOH, NaOH, NaH and potassium-t-butoxide.
• the compound of formula II wherein R 2 and R 1 are each hydrogen is prepared by heating a compound of formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl with an acid.
• the conditions and compositions for use in this process are as indicated above.
• the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl is prepared by treating the compound of the formula II wherein R 2 and R 1 are each hydrogen with a (C 1 -C 6 )alkanol in the presence of an acidic esterification catalyst.
• Suitable esterification catalysts include sulfuric acid, p-toluenesulfonic acid, trifluoromethanesulfonic and thionyl chloride. The reaction is generally carried out at a temperature from about 25° to about 110° C.
• a solvent such as a (C 1 -C 6 )alkanol neat or diluted with a halogenated hydrocarbon or an aromatic hydrocarbon such as CH 2 Cl 2 , CHCl 2 , CHCl 3 and toluene.
• the compound of formula III is prepared by reducing the compound of formula IV.
• Suitable reducing agents include sodium triacetoxyborohydride and sodium cyanoborohydride.
• the reaction is effected in the presence of a (C 1 -C 6 )alkanoic acid such as acetic acid.
• Suitable solvents for use in this process include halogenated hydrocarbons such as CH 2 Cl 2 and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO.
• the reaction may be carried out at a temperature from about 0° to about 75° C.
• the compound of formula IV is prepared by reacting the compound of the formula V with the compound of the formula ##STR30## in the presence of a (C 1 -C 6 )alkanoic acid such as acetic acid.
• the reaction is usually carried out in solvents which include acetic acid, DMF, DMSO and THF at temperatures from about 20° to about 100° C.
• the compound of formula V is prepared by treating the compound of the formula VI with an enamine forming compound either neat or in inert solvents such as aprotic polar solvents.
• Enamine forming compounds include t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals.
• Preferred enamine compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal.
• Solvents for use in this reaction include THF, DMF and the neat reagent.
• Preferred conditions are those wherein the enamine forming compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal and the solvents are THF and DMF, respectively.
• the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl may, alternatively, be prepared by reacting a compound of the formula VII, wherein R 1 and R 2 are as defined above, with the compound of the formula ##STR31## in the presence of a base.
• Suitable bases for use in this aspect of the invention include trialkylamines and cycloheteroarylamines such as triethylamine, pyridine and N-methylmorpholine.
• the reaction is usually carried out in inert solvents which include aprotic polar solvents such as THF, DMF and DMSO and halogenated hydrocarbons such as CH 2 Cl 2 at temperatures from about 0° to about 50° C.
• the compound of formula VII is prepared by reacting a compound of formula VIII wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl with an acid at a temperature from about 50° to about 110° C.
• Suitable acids include concentrated hydrochloric acid and sulfuric acid.
• Solvents which may be used for this reaction include the acid reagent, e.g., the concentrated hydrochloric or sulfuric acid, which can be diluted with a (C 1 -C 4 )alkanoic acid.
• the compound of formula VIII may be prepared by reacting the compound of formula IX with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 , in the presence of a base.
• Suitable bases include alkali metal hydrides, hydroxides and hindered (C 1 -C 6 )alkoxides, such as KOH, NaH and potassium t-butoxide.
• the reaction is generally effected in a solvent such as DMF, DMSO or N-methylpyrrolidine at a temperature from about 25° to about 75° C.
• the compound of formula IX is prepared by reacting the compound of the formula X with the compound of formula ##STR32## in the presence of (CH 3 CO 2 ) 3 NaBH and acetic acid.
• Solvents useful in this aspect of the invention include halogenated hydrocarbons and such as methylene chloride and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO.
• the compound of formula X is prepared by reacting the compound of formula V with a mild organic or mineral acid solution such as acetic or oxalic acid or dilute (0.5-1N) hydrochloric or sulfuric acid, in appropriate solvents such as water, halogenated hydrocarbons and hexanes, at a temperature from about 0° to about 50° C.
• a mild organic or mineral acid solution such as acetic or oxalic acid or dilute (0.5-1N) hydrochloric or sulfuric acid, in appropriate solvents such as water, halogenated hydrocarbons and hexanes, at a temperature from about 0° to about 50° C.
• the neuroleptic activity of the compound of formula I may be demonstrated by methods based on standard procedures.
• adult male Sprague-Dawley rats are pretreated with appropriate doses of the test compound by subcutaneous injection.
• One half hour later, all rats are injected intraperitoneally with 1 mg/kg apomorphine hydrochloride dissolved in an 0.1% ascorbate solution and their behavior evaluated.
• the neuroleptic activity of the compound of formula I makes it useful for treating psychotic disorders in human subjects.
• the compound is useful for treating psychotic disorders of the schizophrenic types, and in particular the compound is useful for removing or ameliorating such symptoms as anxiety, agitation, excessive aggression, tension, and social or emotional withdrawal in psychotic patients.
• the compound of formula I, or a pharmaceutically-acceptable salt thereof can be administered to a human subject either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice.
• the compound can be administered orally or parenterally.
• Parenteral administration includes, especially, intravenous and intramuscular administration.
• the weight ratio of active ingredient to carrier will normally be in the range from 1:6 to 2:1, and preferably 1:4 to 1:1. However, in any given case, the ratio chosen will depend on such factors as the solubility of the active component, the dosage contemplated and the precise route of administration.
• the compound of formula I can be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
• sterile solutions of the active ingredient can be prepared, and the pH of the solutions should be suitably adjusted and buffered.
• the total concentration of solutes should be controlled to render the preparation isotonic.
• the daily dosage will normally be determined by the prescribing physician. Moreover, the dosage will vary according to the age, weight and response of the individual patient as well as the severity of the patient's symptoms. However, in most instances, an effective amount for treating a psychotic disorder will be a daily dosage in the range from 5 to 500 mg, and preferably 50 to 100 mg, in single or divided doses, orally or parenterally.
• the title compound (2.4 g, 50 mmol) from the previous example was dissolved in a mixture of tetrahydrofuran (24 ml) and ethanol (24 ml). Water (16 ml) was added to the stirred solution followed by sodium hydrosulfite (2.03 g, 116 mmol) and the mixture was heated to reflux. After 10 minutes, the solids had dissolved and a second portion of sodium hydrosulfite (1.3 g, 76 mmol) and water were added. The reaction mixture was heated on a steam bath for 4 hours. The reaction mixture was cooled, 6N hydrochloric acid (8.4 ml) was added and the reaction mixture was again heated for 15 minutes on the steam bath.
• the aqueous layer was adjusted to pH 6 with 2N hydrochloric acid and the layers were separated.
• the aqueous layer was extracted with ethyl acetate.
• the combined organic layers were washed with water and brine, dried and filtered.
• the ethyl acetate solution was concentrated to 20 ml and p-toluenesulfonic acid (0.44 g, 2.3 mmol) was added with stirring.
• the tosylate salt of the desired product was collected and dried in vacuo. The yield was 1.27 g, 82.5%. mp 204°- 7° C. Analysis calculated for C 30 H 30 N 5 O 7 Cl 2 S: C, 53.61; H, 4.50; N, 10.42. Found: C, 53.52; H, 4.15; N, 10.70.
• the tosylate salt was dissolved in water and adjusted to a pH of 12 with 1N sodium hydroxide. The basic solution was extracted with ethyl acetate. The ethyl acetate was evaporated to yield the free base as a purple solid, mp 91°-100° C.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Neurology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Psychiatry (AREA)
• Anesthesiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Indole Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (11)

Applications Claiming Priority (1)

Publications (1)

Family

ID=22178273

Family Applications (1)

Country Status (11)

Cited By (15)

Families Citing this family (11)

Citations (5)

Family Cites Families (3)

• 1993
  • 1993-06-28 US US08/083,429 patent/US5359068A/en not_active Expired - Lifetime
• 1994
  • 1994-04-06 JP JP7502611A patent/JP2667987B2/ja not_active Expired - Fee Related
  • 1994-04-06 DK DK94910016T patent/DK0706524T3/da active
  • 1994-04-06 PT PT94910016T patent/PT706524E/pt unknown
  • 1994-04-06 EP EP94910016A patent/EP0706524B1/de not_active Expired - Lifetime
  • 1994-04-06 CA CA002166203A patent/CA2166203C/en not_active Expired - Fee Related
  • 1994-04-06 ES ES94910016T patent/ES2227524T3/es not_active Expired - Lifetime
  • 1994-04-06 AT AT94910016T patent/ATE277041T1/de not_active IP Right Cessation
  • 1994-04-06 DE DE69434020T patent/DE69434020T2/de not_active Expired - Fee Related
  • 1994-04-06 WO PCT/IB1994/000061 patent/WO1995000510A1/en not_active Ceased
• 1995
  • 1995-12-27 FI FI956279A patent/FI119372B/fi active IP Right Grant

Patent Citations (5)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events